---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030557"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:36:46.661715+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma to acquire Increlex from Ipsen for $22.5M upfront plus $7.5M inventory

## Summary
- Acquisition of Increlex (mecasermin injection) for severe primary IGF-1 deficiency; approved in 40 territories.
- Total upfront consideration $30M ($22.5M asset purchase + $7.5M inventory) plus $2.5M on each of first two anniversaries.
- Credit facility expanded to $30M from SWK Holdings; interest at SOFR+6.75%; 289,736 warrant shares at $5.32.
- Ipsen reported 2023 global sales of €17.3M for Increlex; Eton to immediately commercialize in U.S. after closing.
- Closing expected near year-end 2024; all-cash transaction subject to customary conditions.

## SEC filing metadata
- accession: 0001437749-24-030557
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924030557/0001437749-24-030557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924030557/eton20240930_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030557
- JSON: https://secwatch.observer/filing/0001437749-24-030557.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.